Harris RE. Global Epidemiology of Cancer, Jones & Bartlett, 2015.
Harris RE. Epidemiology of Chronic Disease: Global Perspectives, Jones & Bartlett, 2012.
Harris RE. Inflammation in the Pathogenesis of Chronic Diseases: the COX-2 Controversy, Springer, 2007.
Harris RE. COX-2 Blockade in Cancer Prevention and Therapy. Humana Press, 2003.
Harris RE, Casto BC, Harris ZM. Cyclooxygenase-2 and the inflammogenesis of breast cancer. World Journal of Clinical Oncology 5(4): 677-692, 2014.
Harris RE, Beebe J, Al Shafie GA. Reduction in cancer risk by selective and non-selective cyclooxygenase 2 (COX-2) inhibitors. J Exp Pharm, 4, 91-96, 2012.
Harris RE. Cyclooxygenase-2 (COX-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammo-pharmacology. 17:1-13, 2009.
Harris RE, Beebe-Donk J, Alshafie GA. Similar reductions in the risk of human colon cancer by selective and non-selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 8 (237): Aug 14, 2008.
Harris RE, Beebe-Donk J, Alshafie GA. Reduced risk of human lung cancer by selective cyclooxygenase-2 (COX-2) blockade: results of a case control study. International Journal of Biological Sciences, 3(5): 328-334, 2007
Harris RE. COX-2 and the inflammogenesis of cancer. Subcellular Biochemistry, 42: 193-212, 2007.
Harris RE, Beebe-Donk JD, Alshafie GA. Cancer chemoprevention by selective cyclooxygenase-2 (COX-2) blockade: results of case control studies. Subcellular Biochemistry, 42: 83-126, 2007.
Harris RE; Beebe-Donk J; Alshafie GA. Reduction in the risk of human breast cancer by COX-2 inhibitors. Biomed Central (BMC). Cancer, 6:27, 2006.
Harris, RE, Beebe-Donk J. Aspirin, ibuprofen, and other nonsteroidal anti-inflammatory drugs (NSAIDs) in cancer prevention: a critical review (Review). Oncology Reports 13 (4), 559-583, 2005.
Harris RE. Does the dose make the poison? Science 308; 203, 2005.
Harris RE, Sparks A, McTiernan A, Anderson G, White E, Chlebowski RT, Frid D, Jackson R. Inverse association of breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women’s Health Initiative. Cancer Research 63: 6096-6101, 2003.
Harris RE, Beebe-Donk J, Schuller HM. Chemoprevention of lung cancer by non-steroidal anti-inflammatory drugs among cigarette smokers. Oncology Reports 9: 693-395, 2002.
Harris RE, Namboodiri KA, Beebe-Donk, J. Inverse association of malignant melanoma and non-steroidal anti-inflammatory drugs (NSAIDs) in women. Oncology Reports 8: 655-657, 2001.
Harris RE, Alshafie GA, Abou-Issa H, Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Research 60: 2101-2103, 2000.
Harris RE, Kasbari S, Farrar WB. Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer. Oncology Reports 6:71-73, 1999.
Joarder FS, Abou-Issa H, Robertson FM, Parrett ML, Alshafie G, and Harris RE. Growth arrest of DMBA-induced mammary carcinogenesis with ibuprofen treatment in female sprague-dawley rats. Oncology Reports 4:1271-1273, 1997.
Harris RE, Namboodiri KK, Farrar WB. Nonsteroidal anti-inflammatory drugs and breast cancer. Epidemiology 7:203-205, 1996.
Harris RE, Namboodiri KK, Farrar WB. Epidemiologic study of non-steroidal anti-inflammatory drugs and breast cancer. Oncology Reports 2: 591-592, 1995.
Harris RE, Zang EA, Anderson JI, Wynder EL. Race and sex differences in lung cancer risk associated with cigarette smoking. Intl J Epidemiology 22(4): 592-599, 1993.
Harris RE, Namboodiri KK, Wynder EL. Breast cancer risk: Effects of estrogen replacement therapy and body mass. J Natl Cancer Inst 84 (20): 1575-1582, 1992.
Harris RE, Hebert JR, Wynder EL. Cancer risk in male veterans utilizing the veterans administration medical system. Cancer 64: 1160-1168, 1989.
Harris RE, Wynder EL. Breast cancer and alcohol consumption: a study in weak associations. J Am Med Assoc 259(19): 2867-2871, 1988.
Harris RE, Lynch, HT, Guirgis HA. Familial breast cancer: risk to the contralateral breast. J Natl Cancer Inst 60: 955-960, 1978.